DDInter856 DDInter1576
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated hepar
Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.
Regorafenib {u} (Compound) resembles {v} (Compound) Sorafenib
Regorafenib {u} (Compound) binds {v} (Gene) CYP2C9
Regorafenib {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C9 Inhibitors
Regorafenib {u} (Compound) causes {v} (Side Effect) Myocardial infarction
Regorafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dapagliflozin
Regorafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dolutegravir
Regorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Irinotecan
Regorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abametapir
Regorafenib {u} may lead to a major life threatening interaction when taken with {v} Fondaparinux
Regorafenib {u} may lead to a major life threatening interaction when taken with {v} Venetoclax
Regorafenib (Compound) resembles Sorafenib (Compound)
Regorafenib (Compound) binds CYP2C9 (Gene)
Regorafenib (Compound) is included by Cytochrome P450 2C9 Inhibitors (Pharmacologic Class)
Regorafenib (Compound) causes Myocardial infarction (Side Effect)
Regorafenib may cause a minor interaction that can limit clinical effects when taken with Dapagliflozin
Regorafenib may cause a minor interaction that can limit clinical effects when taken with Dolutegravir
Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan
Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Regorafenib may lead to a major life threatening interaction when taken with Fondaparinux
Regorafenib may lead to a major life threatening interaction when taken with Venetoclax